^
Association details:
| Biomarker: | EGFR exon 19 deletion + EGFR C797S |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | VRN11 (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
VRN110755, A New Therapeutic Option for EGFR Mutation-Driven NSCLC with Brain Metastasis or 1st-line Osimertinib-Resistant EGFR Mutations
Published date:
08/08/2023
Excerpt:
In vivo efficacy studies showed that VRN110755 had superior or comparable efficacy to approved EGFR TKIs in osimertinib-resistant EGFR mutants (Del19/C797S and L858R/C797S) and uncommon EGFR mutants, and comparable efficacy to osimertinib even in common activating EGFR mutants (Del19 and L858R).
